Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes (original) (raw)

1998, Bioorganic & Medicinal Chemistry Letters

Abstract

Pyrimidine analogs of the pyridinylimidazole class of CSBP/p38 kinase inhibitors were prepared in an effort to reduce the potent inhibition of hepatic cytochrome P450 observed for the pyridinyl compounds. The substitution of pyrimidin-4-yl, 2-methoxypyrimidin-4-yl, or 2-methylaminopyrimidin-4-yl for pyridin-4-yl effectively dissociates CSBP/p38 kinase from P450 inhibition for this series and furthermore achieves an increase in oral activity.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (18)

  1. Lee, J. C.; Badger, A. M.; Griswold, D. E.; Dunnington, D.; Truneh, A.; Votta, B.; White, J. R.; Young, P. R.; Bender, P. E. Ann. New York Acad. Sci. 1993, 696, 149.
  2. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, 1. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. Nature 1994, 372,739 (b). Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R., Cohen, P.; Gallagher, T. F.; Young, P. R.; Lee, J. C. FEBS Lett. 1995, 364, 229.
  3. a) Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. L. J. Meal Chem. 1996, 39, 3929;
  4. Gallagher, T.; Seibel, G. L.; Kassis, S.: Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier- Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofinunn, G. A.; Sheldrake, P. L.; McDonnell, P. C.: Kumar, S.; Young, P. R.; Adams, J. L. Bioorg. Med. Chem. 1997, 5, 49.
  5. a) Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.: Brown, M. L.; Pargellis, C. A. Nat. Struc. Bio. 1997, 4, 311 (b) Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanis~uny, S.: Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murko, M. A.; Su, M. Chem. & Biol. 1997, 4,423.
  6. The potential of compounds to inhibit P450 was determined using isofonn selective P450 assays based on the method reported by Bloomer, J.C. Clarke, S.E., and Chenery, R.J. Xenobiotica 1995, 9, 917. The assays were performed with substrates present at their Kan concentration, test compounds at 10 uM and used heterologously expressed enzymes. Measured inhibition of human cytochrome P450s for compounds at 10 uM is given as enzyme (% inhibition): SK&F 86002 -1A2(85), 2C9(80), 2C19(64), 3A4(19) and 2D6(22);
  7. SB 203580, 1A2(61), 2C9(75), 2C19(85), 3A4(61) and 2D6(67).
  8. Testa, B.; Jenner, P. Drug Metab. Rev. 1981, 12, I.
  9. Unpublished observations and data reported in Table 2.
  10. Compound 2d was acquired from an outside supplier.
  11. a) Howard, M. O.; Schwartz, L. W.; Newton, J. F.; Quails, C. W. Jr; Yodis, L. A.; Ventre, J. R. Toxicol-Pathol. 1991. 19, 115.
  12. Schwartz, L. W.; Short, B., unpublished observations.
  13. van Leusen, A. M.; Wildeman, J.; Oldenziel, 0. H. J Org. Chem. 1977, 42, 1153.
  14. Bredereck, H.; Sell, R.; Effenberger~ F. Chem. Ber. 1964, 97, 3407.
  15. Mackman, R.; Tschirret-Guth, R. A.: Smith,G.; Hayhurst, G. P.; Ellis, S.W.; Lennard, M. S.; Tucker, G. T.; Wolf, C.R.; Ortiz- de-Montellano, P. R. Arch.Biochem.Biophys. 1996, 331, 134.
  16. Kiln, S. G.; Novak, R. F. Toxicol. Appl. Pharmacol. 1993 120. 257.
  17. Griswold, D. E.; Hillegass, L. M.; Breton, J. J., Esser, K. M.; Adams, J. L. Drugs Exptl. Clin. Res. 1993, 19, 243.
  18. Not included in Table 2 is compound 4c, which lailed to demonstrate statistically significant activity in the mouse LPS-induced TNF assay when dosed orally at 50 mg/kg ( 12% inhibiton). Additional compounds tested in the mouse model at a dose of 50 mg/kg were 4j (21% inh.), 41 (37% inh.) and 4m (33% inh).